Palabras clave
Burden of the disease
Costs
Economic burden
Datos de los fondos
Resumen
Objective: Determine the annual economic burden of the disease from an institutional perspective and based on GINA’s recommended classification in a retrospective cohort of adults treated at Instituto Nacional de Enfermedades Respiratorias (INER) of Mexico City.
Methods: A retrospective, longitudinal observational study comprised by data from 247 female asthma patients, annual direct costs were estimated including: visits, laboratory tests, pharmacological treatment and management of crisis or exacerbations, to determine the annual burden of the disease from an institutional perspective and according to Global Initiative for Asthma classification.
Results: The average annual cost was $43,813.92, which increased in relation to the need of inhaled corticosteroids and long-acting beta agonists dosage increase. The average doctor’s appointment cost was $2,004.57, $982.82 for crisis management and $2,645.95 for laboratory testing. Pharmacological treatment represented the main economic burden with an annual average cost of $38,180.58.
Conclusions: The results highlight an economic burden of asthma estimated at an annual cost per patient of $43,813.92 MXN (SD=93,348.85) in the context of the third level of care in the Mexican public health system. The asthma severity and treatments such as biologics were the main factors that increased direct costs of care.
Referencias
World Health Organization Asthma Fact Sheet. https://www.who.int. [Online].; 2021 [cited 2021 Nov 02. Available from: https://www.who.int/es/news-room/fact-sheets/detail/asthma.
Del-Río-Navarro B, Berber A, Reyes-Noriega N, Navarrete-Rodríguez E, García-Almaraz R, Ellwood P, et al. Global Asthma Network Phase I study in Mexico: prevalence of asthma symptoms, risk factors and altitude associations-a cross-sectional study. BMJ Open Respir Res. 2020 Dec; 7(1): p. e000658.
Flórez-Tanus Á, Parra D, Zakzuk J, Caraballo L, Alvis-Guzmán N. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018 Nov; 11(1).
Mexico’s Health Department. Morbidity Yearbook 1984 - 2019. 2021 https://epidemiologia.salud.gob.mx/anuario/html/morbilidad_nacional.html. Accessed 5th of November 2021. [Text in Spanish]
Ocampo J GRSJ. Prevalence of asthma in Latin America. Critical look at ISAAC and other studies. Rev Alerg Mex. 2017 Apr-Jun; 64(2): 188-197. [Text in Spanish]
Global Initiative for Asthma. 2021 https://ginasthma.org/pocket-guide-for-asthma-management-and-prevention/. Accessed 5th of November 2021.
Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002 Jan; 19(1): 61-67.
World Health Organization. WHO. 2021 https://www.who.int/publications/i/item/who-2019-ncov-sci-brief-asthma-2021.1. Accessed 5th of November 2021.
AGREEMENT number ACDO.AS3.HCT.301120/310.P.DF dictated by the H. Technical Council on their ordinary session on November 30th of 2020, related to the approval of Unitary Costs by Level updated to the year 2021. Official Federation Diary. 28th of December of 2020 [Text in Spanish]
Janson C, Lisspers K, Ställberg B, Johansson G, Telg G, Thuresson M, et al. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR). Respir Res. 2018 Sep; 19(1): p. 168.
Glick, Henry A. and others, Economic Evaluation in Clinical Trials, 2 edn, Handbooks in Health Economic Evaluation (Oxford, 2014; online edn, Oxford Academic, 1 Oct. 2014), https://doi.org/10.1093/med/9780199685028.001.0001 Accessed on April 29th 2022.
Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, FitzGerald JM. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009 May 19;9:24.
Fernández-Vega Margarita, Vargas Mario H., Regalado-Pineda Justino, Chapela-Mendoza Rocío, Salas-Hernández Jorge. Characteristics of the Mexican asthma patient in outpatient clinics. Rev. invest. Clín. 57(4), 513-521. [Text in Spanish]
Mexico’s Superior Audit Department. Performance of Mexico´s National Institute of Respiratory Diseases Ismael Cosío Villegas. Performance audit 2018-1-12NCD-07-1590-2019. 1590-DS. https://www.asf.gob.mx/Trans/Informes/IR2020c/Documentos/Auditorias/2020_0248_a.pdf Accessed 5th of November 2021. [Text in Spanish]
National Institute for Respiratory Diseases. Budget Reports. http://iner.salud.gob.mx/interna/armonizacioncontable_informacionpresupuestal.html. Accessed 5th of November 2021. [Text in Spanish]
Martínez-Moragón E, Climent M, Chiner E, Fernández-Aracil C, Sánchez-Toril F, Lluch-Tortajada I; Effectivenes and pharmacoeconomic analysis of severe asthma treated with omalizumab in the clinical practice.Farm Hosp. 2019;43:101-9. [Text in Spanish]
Entrenas Costa LM, Casas-Maldonado F, Soto Campos JG, Padilla-Galo A, Levy A, Álvarez-Gutiérrez FJ, et al. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. Pharmacoecon Open 2019; 3:333-42
Zein JG, Erzurum SC. Asthma is Different in Women. Curr Allergy Asthma Rep. 2015 Jun;15(6):28.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2023 Revista Alergia México